首页> Journal of nuclear medicine : official publication, Society of Nuclear Medicine> <sup>18</sup>F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2- Metastatic Breast Cancer.

<sup>18</sup>F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2- Metastatic Breast Cancer.

导出 OA

翻译打印收藏纠错

第一作者： Lanell M,Peterson

第一单位： Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington.

作者： Lanell M,Peterson ^[1] ; Brenda F,Kurland ^[2] ; Fengting,Yan ^[1] ; Alena Novakova-,Jiresova ^[3] ; Vijayakrishna K,Gadi ^[4] ; Jennifer M,Specht ^[1] ; Julie R,Gralow ^[1] ; Erin K,Schubert ^[5] ; Jeanne M,Link ^[6] ; Kenneth A,Krohn ^[6] ; Janet F,Eary ^[7] ; David A,Mankoff ^[5] ; Hannah M,Linden ^[8]

作者单位： Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington. ^[1] Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania. ^[2] Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic. ^[3] Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington.;Clinical Research and Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. ^[4] Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania. ^[5] Department of Diagnostic Radiology, Oregon Health and Science University, Portland, Oregon; and. ^[6] Cancer Imaging Program, National Cancer Institute, Bethesda, Maryland. ^[7] Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington hmlinden@uw.edu. ^[8]

关键词 ER+ breast cancer FES estrogen receptors metastatic breast cancer vorinostat